Steve Davis, Acadia CEO
April 19, 2022 07:31 AM EDT
R&D

Aca­di­a's prized pain drug from $52M buy­out flops its first test

Amber Tong

When Aca­dia Phar­ma­ceu­ti­cals put down $52.5 mil­lion in cash to buy out Cer­Sci Ther­a­peu­tics – along with $887 mil­lion in biobucks – in 2020, CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Re­pare to lay off 75% of staff; Cas­tle Creek inks $75M roy­al­ty deal

Al­ny­lam eyes big­ger dis­eases in more tis­sue types at ‘in­flec­tion point’ for siR­NA

Brid­Gene nets an­oth­er Take­da deal amid plans to raise more fund­ing and go pub­lic

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times